Quantcast

Latest Bevacizumab Stories

2014-08-19 08:29:50

VAL-083 Phase I/II VAL-083 clinical trial advances to 50mg/m(2) cohort VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 19, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today a protocol amendment to allow for expanded dosing in its VAL-083 clinical trial had been filed with the U.S. Food and Drug Administration (FDA) and that a new cohort of a new 50mg/m(2) has been opened at three clinical trial sites in the United...

2014-08-14 12:27:38

Over Three-Quarters of Physicians View Ophthotech's Fovista as an Emerging Therapy with High Potential Value for Wet AMD, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 14, 2014 /PRNewswire/ -- Decision Resources Group finds that physician-reported patient shares for Regeneron's Eylea, as well as the other major anti-vascular endothelial growth factor (VEGF) agents Genentech/Roche's Avastin and Genentech/Roche's Lucentis, have now stabilized among wet age-related...

2014-08-05 08:33:58

POINT ROBERTS, Wash. and NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Investorideas.com, a global news source covering leading sectors including biotech, issues an exclusive Q&A interview with Dr. Craig Dionne, PhD, GenSpera's (OTCQB: GNSZ) CEO. Dr. Dionne discusses the company's lead drug G-202 and how they have taken a powerful toxin named thapsigargin to selectively target and kill cancer cells. He also shares insight into the key points that make them different from competitive...

2014-07-14 23:03:57

The Retina Group of New York (RGONY), with offices in Hicksville and Hauppauge, NY, has announced the availability of Ozurdex® (dexamethasone intravitreal implant) as a long-lasting treatment for diabetic macular edema (DME) patients. Hicksville and Hauppauge, NY (PRWEB) July 14, 2014 The Retina Group of New York (RGONY), with offices in Hicksville and Hauppauge, NY, has announced the availability of Ozurdex® (dexamethasone intravitreal implant) as a long-lasting treatment for...

2014-07-12 23:02:37

ResearchMoz presents this most up-to-date research on Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market. View All Therapeutic Area Market Research Reports at http://www.researchmoz.us/therapeutic-area-market-reports-37.html. Albany, NY (PRWEB) July 12, 2014 “Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive...

2014-06-30 13:06:13

European Society for Medical Oncology ESMO 16 World GI Congress on Gastrointestinal Cancer The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. "Around 50% of patients with colorectal cancer develop metastases but eventually many of them do not respond to standard therapies,"...

2014-06-30 12:40:20

European Society for Medical Oncology ESMO 16 World GI Congress on Gastrointestinal Cancer For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. "The CALGB/SWOG 80405 trial was designed and formulated in 2005, and the rationale was simple: we had new drugs --bevacizumab and cetuximab-- and the study...

2014-06-26 12:27:15

LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Colorectal Cancer -- KOL Insight Modulehttp://www.reportbuyer.com/pharma_healthcare/diseases/colorectal_cancer_kol_insight_module.html IntroductionThe global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in cytotoxics and increasing adoption of anti-EGFR products as first line therapies. What will be the impact on market leader...

2014-06-18 23:02:56

New research report “Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany” elaborated by GBI Research is now available at MarketPublishers.com. According to the study, in 2019, the world GBM market value is anticipated to amount to USD 583 million. London, UK (PRWEB) June 18, 2014 Owing to the poor prognosis under presently available treatment options, therapies with high...

2014-06-13 08:23:58

Analysis of PRiDe, a U.S. commercial registry of 457 recurrent glioblastoma patients, demonstrates that patients treated with NovoTTF Therapy at their first recurrence achieved a median overall survival of 20 months NEW YORK, June 13, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that subgroup survival data from its U.S. commercial patient registry will be presented at the 16(th) Biennial Canadian Neuro-Oncology Meeting in Halifax, Nova Scotia,...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.